TQA2226
/ Sino Biopharm, Ampsource Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 23, 2026
A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.
(clinicaltrials.gov)
- P1 | N=14 | Terminated | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=74 ➔ 14 | Trial completion date: Dec 2024 ➔ Mar 2026 | Recruiting ➔ Terminated; Study terminated for strategic business reasons.
Enrollment change • Trial completion date • Trial termination • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
January 01, 2024
A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.
(clinicaltrials.gov)
- P1 | N=74 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
November 22, 2023
A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.
(clinicaltrials.gov)
- P1 | N=74 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 3
Of
3
Go to page
1